Ludwig Enterprises acquires mRNA Neuro Panel patent, serotonin assay IP from Nova Mentis

LUDWIG ENTERPRISES, INC.

Acquired U.S. Patent Application 18/705375 and related IP for mRNA neuro panel and serotonin assay from Nova Mentis.
Issued 750,000 shares of common stock to Nova Mentis, subject to one-year lock-up and quarterly sale limits.
Company will pay a 5% royalty on commercialization: 2.5% each to Nova and Hausman until Hausman recovers $245,712 in unpaid consulting.
IP includes data from ASD/Fragile X observational study and serotonin assays from UCF lab of Dr. Kiminobu Sugaya.
Dr. Marvin Hausman, CSO, says IP represents over 10 years of mRNA research; intends to expand beyond breast cancer screening.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.